JFDI! Working Group

The PROMETHEUS-BLOODPAC study team are conducting the JFDI Phase III study where a limited number of BLOODPAC-JFDI analytic sites will run clinical samples identified as being positive for an oncology variant that was contained in the original contrived materials tested in Phase II (Phase IIIA), or a variant available in more recently developed contrived materials (Phase IIIB). TAGC will conduct one of the four workflows (using Illumina TSO500) as a paired measurement with the same sample, demonstrating its equivalency across sites. Continued collaboration with the Food and Drug Administration (FDA), the College of American Pathologists (CAP), and AMP will enhance the value, learnings, and applicability of the findings.